FLECAINIDE ACETATE Structure. Figure1.

Pharmacokinetics: its absorption is around 90 % and is not affected by food or antiacid agents. The balanced state is obtained after 5 to 7 days. Plasma transportation: 50 % to 70 % bound to plasma proteins. Therapeutic plasma concentration: from 0.2mg/ml to 0.8m/ml up to 1 mg/ml (up to 100mg/ml). Above this value, a toxicity sign could arise; however, in sensitive patients toxicity manifestations could occur in lower values. T (half life): it depends much on urine pH. If acidified 10h and if alkalized 17h. In average from 8h to 14h (mean 11.3h). It increases in renal insufficiency. Organs that metabolize the drug: Liver: 60%. Mediated in a polymorphic way by the P450 2D6 enzyme, producing inactive metabolites and meta-O-delkylate-flecainide with a 20 % activity of the drug. Patients with poor CYP2D6-mediated metabolism (heterozygous-EMs and intermediate and poor metabolizers) showed age-related reduction in flecainide metabolism because metabolism was taken over by CYP1A2, whose activity decreases with age [1] Kidneys: 30 % to 40%. It could be eliminated unaltered. This via is enough to eliminate the drug. It is not removed by dialysis. Its binding with plasma proteins decreases in renal insufficiency. A poor understanding of the elimination routes for anti-arrhythmic drugs and the risks involved when combined with nonsteroidal anti-inflammatory drugs modifying glomerula